10316.1 The PDMP Advisory Committee (“Committee”) shall consist of seven (7) members, three (3) of which shall be ex officio members. The Director of the Department of Health (“Director”) shall appoint the remaining four (4) members, who may be from the public or private sectors, who may serve without residency restrictions, and who shall represent multiple disciplines and stakeholders in the area of prescription drug abuse. Membership of the Committee shall be as follows:

1. (a) The Director, or his or her subordinate designee, who shall serve as chairperson;
2. (b) The Executive Director for the Board of Medicine or his or her subordinate designee;
3. (c) The Executive Director for the Board of Pharmacy or his or her subordinate designee; and
4. (d) Four (4) members who shall represent multiple disciplines and stakeholders in the area of prescription drug abuse, and include representation from the medical and pharmacy practices, the Metropolitan Police Department, and a consumer member.

10316.2 All actions of the Committee shall be taken pursuant to a vote of a majority of the members of the Committee. A majority of the appointed members shall constitute a quorum.

10316.3 The chairperson shall only vote in cases of a tie among Committee members.

10316.4 Each appointed member of the Committee shall serve at the pleasure of the Director. Public members of the Committee shall serve a maximum term of nine (9) years from the date of appointment.

10316.5 Members of the Committee shall not be compensated for time expended in performing Committee duties.

10316.6 The Committee shall convene at least two (2) times per year to advise the Director:

1. (a) On the implementation and evaluation of the Program;

2. (b) On the establishment of criteria for indicators of possible misuse or abuse of covered substances;

3. (c) On standardization of the methodology that should be used for analysis and interpretation of prescription monitoring data;

4. (d) In determining the most efficient and effective manner in which to disclose the findings to proactively inform prescribers regarding the indications of possible abuse or misuse of covered substances;
5. (e) On identifying drugs of concern that demonstrate a potential for abuse and that should be monitored; and
6. (f) Regarding the design and implementation of educational courses for:
7. (1) Persons who are authorized to access the prescription monitoring information;
8. (2) Persons who are authorized to access the prescription monitoring information, but who have violated the laws or breached professional standards involving the prescribing, dispensing, or use of any controlled substances or drugs monitored by the Program;
9. (3) Prescribers on prescribing practices, pharmacology, and identifying, treating, and referring patients addicted to or abusing controlled substances or drugs monitored by the Program; and
10. (4) The public about the use, diversion and abuse of, addiction to, and treatment for the addiction to controlled substances or drugs monitored by the Program.

10316.7 The Committee shall keep minutes of all its meetings.

10316.8 Pursuant to Section 2(b) of the Open Meetings Act, effective March 31, 2011 (D.C. Law 18-350; D.C. Official Code § 2-575(b)), and for the purposes set forth therein, the Committee may also meet in closed session.

SOURCE: Final Rulemaking published at 62 DCR 15828 (December 11, 2015).